Coronavirus disease 2019 (COVID-19) is a clinical condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is characterized by a spectrum of symptoms varying from mild respiratory and/or gastrointestinal to interstitial pneumonia with acute respiratory distress syndrome, multiorgan failure, or death \[[@bib1]\]. COVID-19 started in Huang, China, in December 2019 and has rapidly spread all over the world. The World Health Organization (WHO) declared a pandemic on March 11, 2020 \[[@bib2]\]. The first case of COVID-19 in Italy was reported on February 20, 2020. To contain the rapid spread of the virus, stringent security measures were adopted. However, by April 3, 2020, data from the Italian National Institute of Health showed that 124,527 Italian people tested positive for the new SARS-CoV-2 (of which 51,535 (41%) were in Lombardy), 3994 (3.2%) were admitted to the intensive care unit (ICU), and 15,362 (12.3%) were dead from the disease. This dramatic and overwhelming situation has changed the physiognomy of our hospitals that became COVID-19 centers. COVID-19 severity seems to directly correlate with a patient's age and comorbidities \[[@bib3]\]. Proinflammatory cytokines may play an important role, especially in the most severe form of the disease. As a consequence, transplanted patients appear to be at particularly high risk for infection because of immunosuppressive regimens and comorbidities \[[@bib4]\]. Transplantation is the treatment of choice for many several end-stage diseases, and this scenario has inevitably impacted the management of the donation process \[[@bib5]\]. Several case reports and series on transplanted/waiting list patients have recently been published, with different results according to different organs \[[@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11]\]. North Italy Transplant program (NITp) is a consortium of 6 regions (ie, Lombardy, Veneto, Friuli Venezia Giulia, Liguria, Marche, and the autonomous region of Trento) that has cooperated in donor procurement and transplantation since 1974. Despite local difficulties and donors' management, organ procurement and transplantation activities have been reduced but have continued through the COVID-19 pandemic \[[@bib12]\]. The aim of this study was to investigate COVID-19 (donor-related or hospital-related) incidence and mortality in transplanted recipients in the NITp area in the first 6 weeks of the COVID-19 pandemic.

Material and Methods {#sec1}
====================

Patient cohort and study design {#sec1.1}
-------------------------------

This is a cohort study including all consecutive recipients transplanted in the NITp area from February 20 to April 3, 2020 (6 weeks). The follow-up started after transplantation through May 1, 2020 (at least 4 weeks for each patient), or until death. In case of COVID-19 onset, any symptoms of the disease were reported and registered.

Patients transplanted in a NITp Transplant Center with organs recovered from deceased donors procured in an extra-NITp ICU were included in this study as well. Patients transplanted in an extra-NITp center from deceased donors procured in a NITp ICU were excluded from the study. Recipients

Before transplantation, all recipients were tested for COVID RNA with a nasopharyngeal swab and were excluded if positive. After transplantation, patients were admitted to a COVID-19--free ICU or COVID-19--free ward (for kidney recipients) and were re-tested for COVID RNA in case of symptoms or according to local clinical and safety policy. Immunosuppressive therapies were started according to local protocols.

Pretransplant clinical, demographic, and immunological characteristics were collected, as the transplanted organ functioning. The phone call follow-up was performed by a dedicated coordinating center physician who interacted with clinicians of all transplant units and who recorded the presence, or not, of infected transplanted patients, onset timing, COVID-19 symptoms, and infection course.

Donors {#sec1.2}
------

Donors were classified as standard and non-standard according to the risk of potential transmission of an infective or neoplastic disease based on Centro Nazionale Trapianti guidelines. Solid organs were allocated by emergency criteria or regional rotations according to patients' status.

At the beginning of the COVID-19 outbreak, Centro Nazionale Trapianti recommended the execution of nasopharyngeal swab or bronchoalveolar lavage as alternative in all potential donors to exclude SARS-CoV-2 infection. Subsequently, BAL become mandatory and was performed the day of procurement or within 24 hours before the recovery. In all cases, the SARS-CoV-2 real-time reverse transcription polymerase chain reaction result had to be available before the recovery procedure. In case of SARS-CoV-2 polymerase chain reaction positivity, the donor was declared at unacceptable risk and was not used \[[@bib13]\]. General and clinical donor characteristics were collected for each donor. Organ allocation was classified as prioritized or not prioritized, according to the recipient's status at the time of transplantation.

Outcomes {#sec1.3}
--------

The first outcome was the cumulative incidence of COVID-19 in transplanted patients and COVID-19--related mortality. Any donors, recipients, and recipient-donors matching variables were evaluated as potential predictors of COVID-19 disease.

Statistical analyses {#sec1.4}
--------------------

Continuous variables were expressed as mean values and standard deviation (SD) and compared by independent Student *t* test and Kruskal-Wallis test, where appropriate. Categorical variables were expressed as frequencies and percentage values and compared by χ^2^ test.

Kaplan-Meier survival analyses were performed to assess the cumulative incidence of COVID-19 infection and the different categories of clinical manifestations and mortality.

Statistical analyses were performed within SPSS, version 23.0 (IBM Corporation, Armonk, New York, United States).

Results {#sec2}
=======

From February 20 to April 3, 2020, 56 donors were identified for solid organ donation. The majority of them were identified in Lombardy (19/56, 33.9%) and Veneto (8/56, 14.3%). The donors' mean age was 53 years (SD ± 19.4), and male sex was prevalent (29/56, 51.8%). Brain hemorrhage (30 \[53.6%\]) and postanoxic injury (14 \[25.0%\]) were the main causes for hospitalization. More than a half (38/56, 68%) of patients had a standard risk profile, whereas a no-standard risk was attributed to the remaining 32% (18/56) of donors ([Table 1](#tbl1){ref-type="table"} ).Table 1Donors' General CharacteristicsDonor CharacteristicsNumber (%)Total56Procurement region Liguria1 (1.8) Lombardy19 (33.9) Veneto8 (14.3) Friuli4 (7.1) Provincia Autonoma di Trento3 (5.4) Marche3 (5.4) Extra-NITp18 (32.1)Age, years Mean (± SD)53 (19.4) Median (minimum/maximum)55 (4-85)Sex Women27 (48.2) Men29 (51.8)Reason for hospitalization Brain hemorrhage30 (53.6) Ischemic stroke3 (5.4) Postanoxic injury14 (25.0) Trauma9 (16.1)Risk profile Standard38 (67.9) No-standard18 (22.1)Blood group 022 (39.3) A27 (48.2) B5 (8.9) AB2 (3.6)[^1]

Globally, 140 solid organs were transplanted in 134 recipients, of which 10 of 134 (7.5%) were transplanted at an extra-NITp transplant unit and thus were excluded from the analysis.

Overall, 124 recipients with 130 solid organs were transplanted in the NITp area (ie, 12 \[9.7%\] hearts, 4 \[3.2%\] lungs, 39 \[31.4%\] livers \[including 3 left split-livers and 1 combined liver-kidney transplant\], 67 \[54%\] kidneys, and 2 \[1.6%\] combined kidney-pancreas). Urgent list for heart, lung, and liver transplants were 6 (50%), 0 (0), and 5 (13%), respectively. Male sex was prevalent (76/124, 61.3%), and the mean age at transplantation was 51 years (SD ± 16.6) with a body mass index of 23.5 (SD ± 4.1; normal value 18.5-25). Most patients presented with at least 2 or more comorbidities. As for the procurement, the majority of transplants were performed in Lombardy (60/124, 48.4%) and Veneto (36/124, 29.0%) ([Table 2](#tbl2){ref-type="table"} ).Table 2Recipients' General CharacteristicsRecipient CharacteristicNumber (%)Total124Sex Women48 (38.7) Men76 (61.3)Age, years Mean (± SD)51 (16.6) Median (minimum/maximum)55 (0-76)Age, category 0-179 (7.3) 18-4936 (29.0) 50-6972 (58.1) ≥ 707 (5.6)BMI Mean (± SD)23.5 (4.1) Median (minimum/maximum)23.4 (12-34)BMI, category \< 18.514 (11.3) 18.6-24.967 (54.0) 25-39.942 (33.9) ≥ 401 (0.8)Comorbidities, number 0-121 (18.1) ≥ 295 (81.9)Transplant region Liguria4 (3.2) Lombardy60 (48.4) Veneto36 (29.0) Friuli19 (15.3) Marche5 (4.0)Transplanted organ Heart12 (9.7) Lung4 (3.2) Liver39 (31.4) Whole liver35 (89.8) Left split liver3 (7.7) Right split liver-kidney combined1 (2.5) Kidney67 (54) Single kidney64 (96.0) Dual kidney3 (4.0) Combined kidney-pancreas2 (1.6)Functioning graft No113 (96.8) Yes12 (3.2)Anti-HLA antibodies (no DSA) Negative87 (70.2) Positive37 (29.8)DSA Negative120 (96.8) Positive4 (3.2)[^2]

After transplantation, 5 of 124 (4%) recipients developed COVID-19 after a mean of 13 days (SD ± 6.7) from transplantation, with a cumulative incidence of 4.0% (95% confidence interval \[CI\], 0.5-7.5) ([Fig 1](#fig1){ref-type="fig"} ). They received lung (1 patient), liver (2 patients), and kidney (2 patients) transplantation. All the patients were transplanted from different donors, and no other recipient transplanted with another organ from these 5 donors developed the infection.Fig 1Coronavirus disease 2019 (COVID-19) cumulative incidence. Plotted cumulative incidence curves in the cohort of transplanted recipients: (**A**) in all recipients; (**B**) in male vs female recipients; (**C**) in recipients according transplant regions; (**D**) in recipients with 0 to 1 vs ≥ 2 comorbidities; and (**E**) in recipients according waitlist status.

One liver recipient died of respiratory distress syndrome 8 days after the onset of COVID-19 symptoms and 22 days from transplant. The other 4 patients experienced mild symptoms of the disease, did not change the immunosuppressive therapy, and were discharged from the hospital after a few weeks. The majority of these patients were men (4/5, 80%). They all were older than 50 years of age with 2 or more comorbidities. All patients were transplanted in non emergency waiting list with standard-risk profile or low--infective-risk (hepatitis B virus anticore antigen positivity) donors and in Lombard Transplant Units. Before transplantation, all recipients had a negative donor-recipient crossmatch, 2 of 5 (40%) had pre-formed anti-HLA antibodies, but none was a donor-specific antibody. After transplantation, 5 out of 5 were treated with steroids, 4 of 5 (80%) were treated with FK506, and none received cyclosporine, azathioprine, everolimus, or anti-interleukin 2.

No differences were found in donor and recipient characteristics comparing COVID-19--positive and --negative recipients ([Table 3](#tbl3){ref-type="table"} ).Table 3Reported Recipients and Donors General Characteristics in Coronavirus 2019--Positive and --Negative Transplanted RecipientsTotal RecipientsCOVID-19 NegativeCOVID-19 Positive*P* Value1195Donors' reason for hospitalization, n (%).825 Brain hemorrhage62 (52.5)3 (60.0) Ischemic stroke9 (7.6)0 (0) Postanoxic injury34 (28.8)1 (20) Trauma13 (11.0)1 (20)Donor sex, n (%).648 Women59 (49.6)3 (60) Men60 (50.4)2 (40)Donor age, years.998 Mean (± SD)52 (18.5)52 (15.7) Median (minimum/maximum)53 (4/85)54 (29-66)Donor blood group, n (%).775 048 (40.3)2 (40) A60 (50.4)2 (40) B9 (7.6)1 (20) AB2 (1.7)0 (0)Risk profile, n (%).475 Standard78 (65.5)3 (60) Non-standard25 (21.0)2 (40)Donor procurement region, n (%).854 Liguria3 (2.5)0 (0) Lombardy48 (40.3)3 (60) Veneto15 (12.6)0 (0) Friuli11 (9.2)1 (20) Provincia Autonoma di Trento13 (10.9)0 (0) Marche7 (5.9)0 (0) Extra-NITp22 (18.5)1 (20)Recipient's sex, n (%).648 Women47 (39.5)1 (20) Men72 (60.5)4 (80)Recipient's age, years.115 Mean (± SD)50 (16.7)62 (5.2) Median (minimum/maximum)53 (0/76)61 (55-69)Recipient's age category, n (%).288 0-179 (7.6)0 (0) 18-4936 (30.3)0 (0) 50-6967 (56.3)5 (100) ≥ 707 (5.9)0 (0)BMI.322 Mean (± SD)23 (4.1)25 (3.9) Median (minimum/maximum)23 (1234)25 (20-29)BMI category n (%).600 \< 18.514 (11.8)0 (0) 18.6-24.965 (54.6)2 (40) 25-39.939 (32.8)3 (60) ≥ 400 (0)0 (0)Comorbidities number, n (%).282 0-121 (18.9)0 (0) ≥ 290 (81.1)5 (100)Transplant region, n (%).235 Liguria4 (3.4)0 (0) Lombardy55 (46.2)5 (100) Veneto36 (30.3)0 (0) Friuli19 (16)0 (0) Marche5 (4.2)0 (0)Transplanted organ, n (%).340 Heart12 (10.1)0 (0) Lung3 (2.5)1 (20) Liver37 (31.1)2 (40) Whole liver33 (89.2)2 (100) Left split liver3 (8.1)0 (0) Right split liver-kidney combined1 (2.7)0 (0) Kidney65 (54.6)2 (40) Single kidney62 (95.4)2 (100) Dual kidney3 (4.6)0 (0) Kidney-pancreas combined2 (1.7)0 (0)Functioning graft n (%).455 No107 (89.9)5 (100) Yes12 (10.1)0 (0)Anti-HLA antibodies (no DSA), n (%).634 Negative84 (70.6)3 (60) Positive35 (29.4)2 (40)DSA, n (%).677 Negative115 (96.6)5 (100) Positive4 (3.4)0 (0)[^3]

During follow-up, 5 of 124 (4.0%) recipients died, 1 of COVID-19, with an overall mortality of 4.3% (95% CI, 0.6-8.0) and a COVID-19--related-mortality of 0.8% (95% CI, 0-6.0) ([Fig 2](#fig2){ref-type="fig"} ).Fig 2Overall coronavirus disease 2019 (COVID-19)-related mortality. Plotted mortality curves in transplanted patients. (**A**) The reported overall mortality; and (**B**) the reported COVID-19--related mortality.

Discussion {#sec3}
==========

In our study, COVID-19 had a 4.0% incidence in recipients transplanted during the pandemic, with a specific COVID-19--related mortality of 0.8%. Patients who developed COVID-19 were all more than 50 years old, transplanted in Lombardy, and were mainly men. Pretransplant immunologic status seemed to have no influence in the infection onset. Not surprisingly, 2 of 5 (40%) patients were transplanted and in the most highly affected province in Italy.

We found a lower rate of COVID-19 compared to recently published papers, where patients transplanted before the outbreak and/or on the waitlist were included \[[@bib9], [@bib10], [@bib11]\]. This difference could be explained by the fact that after the "mediatic explosion" of the infection, prevention and safety measure have been implemented to avoid the wide spread of the virus. In procuring hospitals and in hospitals with Transplants Units, COVID-19 free pathways were created with the aim of reducing the possible transmission of the virus. Moreover, donors' COVID-19 testing has been considered mandatory and all donors have been carefully studied to avoid a possible donor-related virus transmission \[[@bib13]\]. On the other hand, compared to another study of 200 previously "COVID-19 era" pediatric recipients, we found 5 cases vs no confirmed cases. These results might be explained by the different cohorts of patients: adults and pediatric patients transplanted in any NITp transplant units compared to only pediatric recipients, all transplanted and followed in Bergamo \[[@bib7]\].

Our data and the very low mortality rate (only 1 patient) support the safety of continuing donation and transplant process if procurement and transplant procedures follow a COVID-19--free pathway for both donors and recipients. This is reinforced by the evidence that all the patients were transplanted from different donors, and no other recipient transplanted with another organ from these 5 donors developed the infection.

In addition, general characteristics of transplanted patients developing COVID-19 did not differ from the COVID-19--positive general population \[[@bib4]\], supporting the hypothesis that transplant, per se, seemed to not be a risk factor for the infection.

Some limitations need to be addressed. The main one is the short and variable follow-up to assess the actual incidence of post-transplant SARS-CoV-2 infection. However, all transplanted patients were followed for at least 4 weeks, and that period seems to be reasonably long enough to be confident in excluding a donor-related transmission. Because of the low incidence of COVID-19, this study does not have enough power to find any correlation between recipient/donor characteristics and COVID-19 positivity, although this is, to our knowledge, the first study on patients transplanted in the COVID-19 era. As donation is still challenging and limited in number, we chose to include all consecutive transplanted recipients from different transplant units referred to our coordinating center. This may result in possible selection bias from different immunosuppressive therapy, treatment protocols, and monitoring, but our study was aimed to give a complete picture of real life. Data were all collected by call survey. We are confident that we have not missed any new COVID-19 diagnoses given the attention to this infection.

In conclusion, among transplanted patients in the COVID-19 era, the incidence of infection and its mortality is very low. Considering that transplant is the treatment of choice for several end-stage diseases, this infective risk may be considered acceptable because of the real benefit of transplant procedures for the health and quality of life of patients waiting for a solid organ. Further studies with a longer follow-up period are mandatory to confirm the safety of transplant procedures.

[^1]: Abbreviations: NITp, North Italy Transplant program; SD, standard deviation.

[^2]: Abbreviations: BMI, body mass index; DSA, donor-specific antibody; SD, standard deviation.

[^3]: Abbreviations: BMI, body mass index; COVID-19, coronavirus 2019; DSA, donor-specific antibody; NITp, North Italy Transplant program; SD, standard deviation.
